Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations

Martin Reck,G. Shankar,Anthony Lee,Shelley Coleman,Mark McCleland,Vassiliki A. Papadimitrakopoulou,Mark A. Socinski,Alan Sandler

Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations

2020

Martin Reck
G. Shankar
Anthony Lee
Shelley Coleman
Mark McCleland
Vassiliki A. Papadimitrakopoulou
Mark A. Socinski
Alan Sandler

ABSTRACTIntroduction: Cancer immunotherapy has revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). However, specific patient groups (e.g. patien...

Keywords:

Atezolizumab
Intensive care medicine
Bevacizumab
Cancer immunotherapy
Internal medicine
Bevacizumab/paclitaxel
Oncology
first line
Medicine
Squamous non-small cell lung cancer
non small cell
Carboplatin
Lung cancer
non squamous
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations